FGF2 and neoplasm: To extend these findings, we treated ESCC tumor-bearing mice (induced by either KYSE30 or EC9706 cells) with FGF2 neutralizing antibody for 20 days and analyzed the effects on tumorigenesis and infiltrated FGFR2+ CAFs.